Cancer Genetics (Cancer Genetics) Cash-to-Debt : 6.75 (As of Dec. 2020)

Cancer Genetics Cash-to-Debt Chart

Cancer Genetics Annual Data
	Trend	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
Cash-to-Debt		Get a 7-Day Free Trial					1.85	0.87	0.06	2.34	6.75

Cancer Genetics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Cash-to-Debt	Get a 7-Day Free Trial															2.34	2.20	2.58	6.29	6.75

Competitive Comparison of Cancer Genetics's Cash-to-Debt

For the Biotechnology subindustry, Cancer Genetics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Genetics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cancer Genetics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cancer Genetics's Cash-to-Debt falls into.

Cancer Genetics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cancer Genetics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2020 is calculated as:

Cancer Genetics's Cash to Debt Ratio for the quarter that ended in Dec. 2020 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cancer Genetics  (NAS:CGIX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cancer Genetics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cancer Genetics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Genetics (Cancer Genetics) Business Description